Share

We are delighted to announce that, at the Board meeting on 17th January, George Sutherland was appointed as the first Chairman of TRUEinvivo Ltd. George originally joined our advisory board in 2017 and then became a shareholder and investor director in February 2018. He has been instrumental in helping us find investment partners, notably Nexus Investment Ventures Ltd., whose network members invested around 70% of our first seed round.
George is CEO of the Sutherland Health Group and has a background in medical device companies and major fast moving consumer goods. He has managed business with most of the major UK retailers and Amazon and over 25 years of experience in dealing with the NHS. He has set up, and run private companies, has raised corporate finance pre and post IPO, and founded and run a public company.
Related Posts
TrueInvivo’s® DOSEmapper™ showcased at BRSS, ensuring precise gamma knife dosimetry and improved radiation safety.
TRUEinvivo wins Business Innovation of the Year Award for DOSEmapper™ technology, revolutionizing radiotherapy safety.
USA patent granted for DOSEmapper™ TLD bead strings & Automated Reader.
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.

